PRESS RELEASE

Q2 2023 — Recast press release

Q2 2023PDF · 21 pages1.2 MB
FOR IMMEDIATE RELEASE
Johnson & Johnson Announces Updated Financials and 2023 Guidance
Following Completion of the Kenvue Separation
• Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of
7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19
Vaccine
• Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting
increased growth of 12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting
increased growth of 11.5% at the mid-point
• Company reduced outstanding share count by approximately 191 million; 2023 guidance reflects only
a partial-year benefit of approximately 73.5 million shares or $0.28 benefit to EPS
• Company secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public
offering and maintains 9.5% of equity stake in Kenvue
• Company maintains its quarterly dividend of $1.19 per share
New Brunswick, N.J., (August 30, 2023) – Johnson & Johnson (NYSE: JNJ) (“the Company”) today announced
updates to its financials and 2023 guidance which reflect its operations as a company focused on transformational
innovation in Pharmaceutical and MedTech. The Company has published a recorded webinar for investors to provide
additional context behind the updated financials and 2023 guidance found in this release, which may be accessed
by visiting the Investors section of the Company's website at webcasts & presentations.
“The completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech
company focused on delivering transformative healthcare solutions to patients,” said Joaquin Duato, Chairman of
the Board and Chief Executive Officer. “We are incredibly proud of the focus and dedication of our employees
worldwide to achieve this milestone, which we are confident will unlock near- and long-term value for all of our
stakeholders.”
As previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue
Inc., formerly Johnson & Johnson’s Consumer Health business. As a result of the completion of the exchange offer,
Johnson & Johnson will now present its Consumer Health business financial results as discontinued operations,
including a gain of approximately $20 billion in the third quarter of 2023.

-- 1 of 21 --

Unless otherwise noted, the financial results and earnings guidance included below have been recast to reflect the
continuing operations of Johnson & Johnson.
FINANCIAL RESULTS
SIX MONTHS
($ in Millions, except EPS) 2023 2022 % Change
Reported Sales $42,413 $40,055 5.9%
Net Earnings $4,885 $8,833 (44.7)%
EPS (diluted) $1.86 $3.31 (43.8)%
SIX MONTHS
Non-GAAP* ($ in Millions, except EPS) 2023 2022 % Change
Operational Sales1,2 8.0%
Adjusted Operational Sales1,3 6.4%
Adjusted Net Earnings1,4 $13,070 $12,426 5.2%
Adjusted EPS (diluted) 1,4 $4.97 $4.66 6.7%
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Note: Values may have been rounded
REGIONAL SALES RESULTS
SIX MONTHS % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. $22,439 $20,367 10.2% 10.2 - 7.6
International 19,974 19,688 1.5 5.8 (4.3) 5.4
Worldwide $42,413 $40,055 5.9% 8.0 (2.1) 6.4
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded
SEGMENT SALES RESULTS
SIX MONTHS % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
Pharmaceutical 27,144 26,186 3.7 5.5 (1.8) 5.6
MedTech 15,269 13,869 10.1 12.8 (2.7) 8.1
Worldwide $42,413 $40,055 5.9% 8.0 (2.1) 6.4
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded

-- 2 of 21 --

UPDATED FULL-YEAR 2023 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company
is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These
items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS; Shares in Millions) August 2023
(excl. Consumer Health)
July 2023
(incl. Consumer Health)6
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point 6.2% – 7.2% / 6.7% 6.0% – 7.0% / 6.5%
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
$83.6B – $84.4B / $84.0B
7.5% – 8.5% / 8.0%
$99.3B – $100.3B / $99.8B
7.0% – 8.0% / 7.5%
Reported Sales3,5 / Mid-point
Change vs. Prior Year / Mid-point
$83.2B – $84.0B / $83.6B
7.0% – 8.0% / 7.5%
$98.8B – $99.8B / $99.3B
6.5% – 7.5% / 7.0%
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
$9.90 – $10.00 / $9.95
11.0% – 12.0% / 11.5%
$10.60 – $10.70 / $10.65
4.5% – 5.5% / 5.0%
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.00 – $10.10 / $10.05
12.0% – 13.0% / 12.5%
$10.70 – $10.80 / $10.75
5.5% – 6.5% / 6.0%
Average Shares Outstanding (Diluted) ~2,557.28 2,630.77
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: July 2023 = $1.09 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
6 The July 2023 financial measures that were previously communicated reflect amounts before the separation of Kenvue and therefore include the
Consumer Health results
7 Average shares outstanding (Diluted) as reported on Q2 2023 Form 10-Q
8 Full Year 2023 Projected Average Shares Outstanding (Diluted) only reflects impact from the Kenvue exchange offer
Note: percentages may have been rounded
Following completion of the Kenvue exchange offer, the Company has reduced its outstanding share count by the
approximately 191 million shares of common stock accepted in the exchange offer.
The weighted average shares outstanding used in the calculation of the August 2023 Guidance for Adjusted Diluted
EPS reflects the net reduction of approximately 73.5 million shares of Johnson & Johnson outstanding common

-- 3 of 21 --

stock as a result of the Kenvue exchange offer. Because this net reduction occurred on August 23, 2023, Johnson
& Johnson will recognize only a partial-year benefit of $0.28 to its full-year 2023 Adjusted Diluted EPS.
The Company generated $13.2 billion in cash proceeds as result of the Kenvue debt offering and initial public
offering. Additionally, Johnson & Johnson maintains a 9.5% stake in Kenvue common stock, which provides the
Company the opportunity to monetize the retained stake in a tax efficient manner in the next year, subject to a
current 90-day lockup agreement. Johnson & Johnson is under no obligation to do so if market conditions are not
supportive.
The Company will maintain its quarterly dividend of $1.19 per share.
WEBINAR INFORMATION:
Johnson & Johnson has published a recorded webinar for investors to provide additional context behind the updated
financials and 2023 guidance found in this release. This webinar, along with supplemental information, may be
accessed by visiting the Investors section of the Company's website at webcasts & presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of
life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our
reach and size for good. We strive to improve access and affordability, create healthier communities, and put a
healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and
ingenuity to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net
earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding
after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be
considered replacements for, and should be read together with, the most comparable GAAP financial measures.
Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying financial schedules of the release and the
Investors section of the Company's website at webcasts & presentations.
Copies of the financial schedules accompanying this release are available on the Company’s website at webcasts
& presentations. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, and reconciliations of non-GAAP financial measures.

-- 4 of 21 --

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act
of 1995 regarding, among other things: future operating and financial performance, product development, and
market position and business strategy. The reader is cautioned not to rely on these forward-looking statements.
These statements are based on current expectations of future events. If underlying assumptions prove inaccurate
or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations
and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors,
such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent in new product research and development,
including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for
new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to
successfully execute strategic plans, including restructuring plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety
concerns resulting in product recalls or regulatory action; significant adverse litigation or government action,
including related to product liability claims; changes to applicable laws and regulations, including tax laws and global
health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems
and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to
realize the anticipated benefits from the separation of the Company’s Consumer Health business; and the New
Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and
descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on
Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding
Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly
Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking
statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake
to update any forward-looking statement as a result of new information or future events or developments.
Press Contacts: Investor Contacts:
Jake Sargent Jessica Moore
media-relations@its.jnj.com investor-relations@its.jnj.com

-- 5 of 21 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	10,782	$ 	9,857 	9.4 % 	9.4 	-
Europe 	5,590 	5,341 	4.7 	9.4 	(4.7)
Western Hemisphere excluding U.S. 	1,076 	998 	7.8 	15.5 	(7.7)
Asia-Pacific, Africa 	3,446 	3,644 	(5.4) 	3.1 	(8.5)
International 	10,112 	9,983 	1.3 	7.7 	(6.4)
Worldwide 	20,894	$ 	19,840 	5.3 % 	8.5 	(3.2)
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,657	$ 	10,510 	10.9 % 	10.9 	-
Europe 	5,131 	5,355 	(4.2) 	(5.2) 	1.0
Western Hemisphere excluding U.S. 	1,136 	1,027 	10.7 	16.8 	(6.2)
Asia-Pacific, Africa 	3,595 	3,323 	8.2 	14.3 	(6.1)
International 	9,862 	9,705 	1.6 	3.8 	(2.2)
Worldwide 	21,519	$ 	20,215 	6.5 % 	7.5 	(1.0)
(Unaudited; Dollars in Millions)
2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	22,439	$ 	20,367 	10.2 % 	10.2 	-
Europe 	10,721 	10,696 	0.2 	2.1 	(1.9)
Western Hemisphere excluding U.S. 	2,212 	2,025 	9.3 	16.2 	(6.9)
Asia-Pacific, Africa 	7,041 	6,967 	1.1 	8.5 	(7.4)
International 	19,974 	19,688 	1.5 	5.8 	(4.3)
Worldwide 	42,413	$ 	40,055 	5.9 % 	8.0 	(2.1)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
Percent Change
FIRST QUARTER
Percent Change
SECOND QUARTER
Percent Change
SIX MONTHS

-- 6 of 21 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	9,857	$ 	9,500 	3.8 % 	3.8 	-
Europe 	5,341 	4,727 	13.0 	21.2 	(8.2)
Western Hemisphere excluding U.S. 	998 	968 	3.0 	4.2 	(1.2)
Asia-Pacific, Africa 	3,644 	3,485 	4.6 	8.3 	(3.7)
International 	9,983 	9,180 	8.7 	14.5 	(5.8)
Worldwide 	19,840	$ 	18,680 	6.2 % 	9.1 	(2.9)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	10,510	$ 	10,168 	3.4 % 	3.4 	-
Europe 	5,355 	4,936 	8.5 	22.1 	(13.6)
Western Hemisphere excluding U.S. 	1,027 	933 	10.2 	13.2 	(3.0)
Asia-Pacific, Africa 	3,323 	3,421 	(2.9) 	6.2 	(9.1)
International 	9,705 	9,290 	4.5 	15.4 	(10.9)
Worldwide 	20,215	$ 	19,458 	3.9 % 	9.1 	(5.2)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	10,794	$ 	10,338 	4.4 % 	4.4 	-
Europe 	4,844 	4,833 	0.2 	16.1 	(15.9)
Western Hemisphere excluding U.S. 	1,059 	1,019 	3.9 	9.1 	(5.2)
Asia-Pacific, Africa 	3,299 	3,336 	(1.1) 	11.4 	(12.5)
International 	9,202 	9,188 	0.1 	13.6 	(13.5)
Worldwide 	19,996	$ 	19,526 	2.4 % 	8.7 	(6.3)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	10,820	$ 	10,634 	1.7 % 	1.7 	-
Europe 	5,124 	6,099 	(16.0) 	(6.3) 	(9.7)
Western Hemisphere excluding U.S. 	1,024 	1,007 	1.7 	8.3 	(6.6)
Asia-Pacific, Africa 	2,971 	3,336 	(10.9) 	3.0 	(13.9)
International 	9,119 	10,442 	(12.7) 	(1.9) 	(10.8)
Worldwide 	19,939	$ 	21,076 	(5.4) % 	(0.1) 	(5.3)
(Unaudited; Dollars in Millions)
2022 	2021 	Total Operations Currency
Sales to customers by
geographic area
U.S. 	41,981	$ 	40,640 	3.3 % 	3.3 	-
Europe 	20,664 	20,595 	0.3 	12.1 	(11.8)
Western Hemisphere excluding U.S. 	4,108 	3,927 	4.6 	8.7 	(4.1)
Asia-Pacific, Africa 	13,237 	13,578 	(2.5) 	7.2 	(9.7)
International 	38,009 	38,100 	(0.2) 	10.0 	(10.2)
Worldwide 	79,990	$ 	78,740 	1.6 % 	6.5 	(4.9)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
THIRD QUARTER
FIRST QUARTER
Percent Change
SECOND QUARTER
Percent Change
Percent Change
FOURTH QUARTER
Percent Change
TWELVE MONTHS
Percent Change

-- 7 of 21 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent 	Percent 	Percent
Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales
Sales to customers 	20,894	$ 	100.0 	21,519	$ 	100.0 	42,413	$ 	100.0
Cost of products sold 	6,687 	32.0 	6,462 	30.0 	13,149 	31.0
Gross Profit 	14,207 	68.0 	15,057 	70.0 	29,264 	69.0
Selling, marketing and administrative expenses 	4,906 	23.5 	5,396 	25.1 	10,302 	24.3
Research and development expense 	3,455 	16.6 	3,703 	17.2 	7,158 	16.9
In-process research and development Impairments 	49 	0.2 	- 	- 	49 	0.1
Interest income 	(198) 	(0.9) 	(326) 	(1.5) 	(524) 	(1.2)
Interest expense, net of portion capitalized 	212 	1.0 	217 	1.0 	429 	1.0
Other (income) expense, net 	6,940 	33.2 	(384) 	(1.8) 	6,556 	15.5
Restructuring 	130 	0.6 	145 	0.7 	275 	0.6
Earnings/(loss) before provision for taxes on income 	(1,287) 	(6.2) 	6,306 	29.3 	5,019 	11.8
Provision for/(Benefit from) taxes on income 	(796) 	(3.9) 	930 	4.3 	134 	0.3
Net earnings/(loss) from Continuing Operations 	(491)	$ 	(2.3) 	5,376	$ 	25.0 	4,885	$ 	11.5
Net earnings/(loss) from Discontinued Operations, net of tax 	423 	(232) 	191
Net earnings/(loss) 	(68)	$ 	5,144	$ 	5,076	$
Net Earnings (loss) per Share (Diluted) from Continuing Operations 	(0.19)	$ 	2.05	$ 	1.86	$
Net Earnings (loss) per Share (Diluted) from Discontinued Operations 	0.16	$ 	(0.09)	$ 	0.07	$
Average shares outstanding (Diluted) 	2,605.5 * 	2,625.7 	2,630.7
*Basic Shares used as in an overall loss position
Effective tax rate from Continuing Operations 	61.8 % 	14.7 % 	2.7 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from continuing operations 	7,536	$ 	36.1 	8,005	$ 	37.2 	15,541	$ 	36.6
Net earnings from continuing operations 	6,340	$ 	30.3 	6,730	$ 	31.3 	13,070	$ 	30.8
Net earnings per share (Diluted) from continuing operations 	2.41	$ 	2.56	$ 	4.97	$
Average shares outstanding (Diluted) 	2,634.3 	2,625.7 	2,630.7
Effective tax rate from continuing operations 	15.9 % 	15.9 % 	15.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
2023
Q1 	Q2 	SIX MONTHS

-- 8 of 21 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent 	Percent 	Percent 	Percent 	Percent 	Percent
Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales 	Amount 	to Sales
Sales to customers 	19,840	$ 	100.0 	20,215	$ 	100.0 	40,055	$ 	100.0 	19,996	$ 	100.0 	19,939	$ 	100.0 	79,990	$ 	100.0
Cost of products sold 	6,018 	30.3 	6,322 	31.3 	12,340 	30.8 	6,172 	30.9 	6,084 	30.5 	24,596 	30.7
Gross Profit 	13,822 	69.7 	13,893 	68.7 	27,715 	69.2 	13,824 	69.1 	13,855 	69.5 	55,394 	69.3
Selling, marketing and administrative expenses 	4,812 	24.3 	5,120 	25.3 	9,932 	24.8 	4,975 	24.9 	5,339 	26.8 	20,246 	25.3
Research and development expense 	3,355 	16.9 	3,585 	17.7 	6,940 	17.3 	3,485 	17.4 	3,710 	18.6 	14,135 	17.7
In-process research and development Impairments 	610 	3.1 	- 	- 	610 	1.5 	- 	- 	173 	0.8 	783 	1.0
Interest income 	(22) 	(0.1) 	(64) 	(0.3) 	(86) 	(0.2) 	(150) 	(0.8) 	(254) 	(1.3) 	(490) 	(0.6)
Interest expense, net of portion capitalized 	10 	0.1 	38 	0.2 	48 	0.1 	51 	0.3 	177 	0.9 	276 	0.3
Other (income) expense, net 	(210) 	(1.1) 	(1) 	0.0 	(211) 	(0.5) 	226 	1.1 	795 	4.0 	810 	1.0
Restructuring 	64 	0.3 	71 	0.4 	135 	0.4 	65 	0.3 	75 	0.4 	275 	0.4
Earnings before provision for taxes on income 	5,203 	26.2 	5,144 	25.4 	10,347 	25.8 	5,172 	25.9 	3,840 	19.3 	19,359 	24.2
Provision for taxes on income 	632 	3.2 	882 	4.3 	1,514 	3.7 	862 	4.3 	613 	3.1 	2,989 	3.7
Net earnings from Continuing Operations 	4,571 	23.0 	4,262	$ 	21.1 	8,833	$ 	22.1 	4,310	$ 	21.6 	3,227	$ 	16.2 	16,370	$ 	20.5
Net earnings from Discontinued Operations, net of tax 	578 	552 	1,130 	148 	293 	1,571
Net earnings 	5,149	$ 	4,814	$ 	9,963	$ 	4,458	$ 	3,520	$ 	17,941	$
Net Earnings per Share (Diluted) from Continuing Operations 	1.71	$ 	1.60	$ 	3.31	$ 	1.62	$ 	1.22	$ 	6.14	$
Net Earnings per Share (Diluted) from Discontinued Operations 	0.22	$ 	0.20	$ 	0.42	$ 	0.06	$ 	0.11	$ 	0.59	$
Average shares outstanding (Diluted) 	2,666.5 	2,667.9 	2,669.2 	2,661.3 	2,650.1 	2,663.9
Effective tax rate from Continuing Operations 	12.1 % 	17.1 % 	14.6 % 	16.7 % 	16.0 % 	15.4 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from continuing operations 	7,349	$ 	37.0 	7,082	$ 	35.0 	14,431	$ 	36.0 	7,060	$ 	35.3 	6,482	$ 	32.5 	27,973	$ 	35.0
Net earnings from continuing operations 	6,388	$ 	32.2 	6,038	$ 	29.9 	12,426	$ 	31.0 	5,938	$ 	29.7 	5,432	$ 	27.2 	23,796	$ 	29.7
Net earnings per share (Diluted) from continuing operations 	2.40	$ 	2.26	$ 	4.66	$ 	2.23	$ 	2.05	$ 	8.93	$
Average shares outstanding (Diluted) 	2,666.5 	2,667.9 	2,669.2 	2,661.3 	2,650.1 	2,663.9
Effective tax rate from continuing operations 	13.1 % 	14.7 % 	13.9 % 	15.9 % 	16.2 % 	14.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
2022
Q1 	Q2 	SIX MONTHS 	Q3 	Q4 	FULL YEAR

-- 9 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	Q1 	Q2 	SIX MONTHS
Net Earnings/(loss) from Continuing Operations, after tax - as reported 	($491) 	$5,376 	$4,885
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,122 	1,130 	2,252
Litigation related 	6,900 	137 	7,037
IPR&D impairments 	49 	0 	49
Restructuring related 	130 	145 	275
Acquisition, integration and divestiture related 	42 	38 	80
(Gains)/losses on securities 	72 	(1) 	71
Medical Device Regulation 	64 	85 	149
COVID-19 Vaccine related costs 	444 	165 	609
Tax Adjustments
Tax impact on special item adjustments 	(1,980) 	(307) 	(2,287)
Consumer Health separation tax related costs 	11 	(17) 	(6)
Tax legislation and other tax related 	(23) 	(21) 	(44)
Adjusted Net Earnings from continuing operations, after tax 	$6,340 	$6,730 	$13,070
Average shares outstanding (Diluted) 	2,634.3 	2,625.7 	2,630.7
Adjusted net earnings per share from continuing operations (Diluted) 	$2.41 	$2.56 	$4.97
2023

-- 10 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	Q1 	Q2 	Q3 	Q4 	FULL YEAR
Net Earnings from Continuing Operations, after tax - as reported 	$4,571 	$4,262 	$4,310 	$3,227 	$16,370
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,014 	995 	958 	977 	3,944
Litigation related 	0 	385 	219 	262 	866
IPR&D impairments 	610 	0 	0 	173 	783
Restructuring related 	58 	103 	92 	119 	372
Acquisition, integration and divestiture related 	0 	0 	0 	196 	196
(Gains)/losses on securities 	411 	109 	164 	6 	690
Medical Device Regulation 	60 	70 	78 	88 	296
COVID-19 Vaccine related costs 	0 	276 	377 	821 	1,474
Other 	(7) 	0 	0 	0 	(7)
Tax Adjustments
Tax impact on special item adjustments 	(346) 	(242) 	(312) 	(394) 	(1,294)
Consumer Health separation tax related costs 	96 	2 	(36) 	4 	66
Tax legislation and other tax related 	(79) 	78 	88 	(47) 	40
Adjusted Net Earnings from continuing operations, after tax 	$6,388 	$6,038 	$5,938 	$5,432 	$23,796
Average shares outstanding (Diluted) 	2,666.5 	2,667.9 	2,661.3 	2,650.1 	2,663.9
Adjusted net earnings per share from continuing operations (Diluted) 	$2.40 	$2.26 	$2.23 	$2.05 	$8.93
2022

-- 11 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Q2 	SIX MONTHS
WW As Reported 	5.3% 	6.5% 	5.9%
U.S. 	9.4% 	10.9% 	10.2%
International 	1.3% 	1.6% 	1.5%
WW Currency 	(3.2) 	(1.0) 	(2.1)
U.S. 	- 	- 	-
International 	(6.4) 	(2.2) 	(4.3)
WW Operational 	8.5% 	7.5% 	8.0%
U.S. 	9.4% 	10.9% 	10.2%
International 	7.7% 	3.8% 	5.8%
Abiomed 	(1.6) 	(1.6) 	(1.6)
U.S. 	(2.7) 	(2.6) 	(2.6)
International 	(0.6) 	(0.6) 	(0.6)
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.0
U.S. 	0.0 	0.0 	0.0
International 	0.1 	0.2 	0.2
WW Adjusted Operational 	6.9% 	6.0% 	6.4%
U.S. 	6.7% 	8.3% 	7.6%
International 	7.2% 	3.4% 	5.4%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
2023 ACTUAL vs. 2022 ACTUAL
Total Enterprise
Q1

-- 12 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Q2 	SIX MONTHS 	Q3 	NINE MONTHS 	Q4 	TWELVE MONTHS
WW As Reported 	6.2% 	3.9% 	5.0% 	2.4% 	4.1% 	(5.4)% 	1.6%
U.S. 	3.8% 	3.4% 	3.6% 	4.4% 	3.8% 	1.7% 	3.3%
International 	8.7% 	4.5% 	6.6% 	0.1% 	4.5% 	(12.7)% 	(0.2)%
WW Currency 	(2.9) 	(5.2) 	(4.1) 	(6.3) 	(4.8) 	(5.3) 	(4.9)
U.S. 	- 	- 	- 	- 	- 	- 	-
International 	(5.8) 	(10.9) 	(8.4) 	(13.5) 	(10.0) 	(10.8) 	(10.2)
WW Operational 	9.1% 	9.1% 	9.1% 	8.7% 	8.9% 	(0.1)% 	6.5%
U.S. 	3.8% 	3.4% 	3.6% 	4.4% 	3.8% 	1.7% 	3.3%
International 	14.5% 	15.4% 	15.0% 	13.6% 	14.5% 	(1.9)% 	10.0%
Abiomed 	(0.1)
U.S. 	(0.3)
International 	0.0
All Other Acquisitions and Divestitures 	0.0 	0.1 	0.1 	0.1 	0.1 	0.1 	0.0
U.S. 	0.0 	0.1 	0.0 	0.1 	0.0 	0.1 	0.0
International 	0.0 	0.1 	0.1 	0.1 	0.1 	0.1 	0.1
WW Adjusted Operational 	9.1% 	9.2% 	9.2% 	8.8% 	9.0% 	(0.1)% 	6.5%
U.S. 	3.8% 	3.5% 	3.6% 	4.5% 	3.8% 	1.5% 	3.3%
International 	14.5% 	15.5% 	15.1% 	13.7% 	14.6% 	(1.8)% 	10.1%
Adjusted Operational Sales Growth
2022 ACTUAL vs. 2021 ACTUAL
Note: Percentages are based on actual, non-rounded figures and may not sum
Total Enterprise
Q1

-- 13 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,402 	1,409 	(7,098) 	(1,287)
% to Sales 	32.8% 	18.8% 	-34.0% 	-6.2%
Intangible asset amortization expense 	739 	383 	- 	1,122
In-process research and development Impairments 	- 	49 	- 	49
Litigation Related 	- 	- 	6,900 	6,900
Loss/(gain) on securities 	38 	34 	- 	72
Restructuring related 	130 	- 	- 	130
Acquisition, integration and divestiture related 	- 	42 	- 	42
Medical Device Regulation 	- 	64 	- 	64
COVID-19 Vaccine related costs 	444 	- 	- 	444
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,753 	1,981 	(198) 	7,536
% to Sales 	42.9% 	26.5% 	-0.9% 	36.1%
Q1 2023 - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total

-- 14 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,812 	1,671 	(177) 	6,306
% to Sales 	35.0% 	21.5% 	-0.8% 	29.3%
Intangible asset amortization expense 	748 	382 	- 	1,130
In-process research and development Impairments 	- 	- 	- 	-
Litigation Related 	(93) 	60 	170 	137
Loss/(gain) on securities 	38 	(39) 	- 	(1)
Restructuring related 	145 	- 	- 	145
Acquisition, integration and divestiture related 	- 	38 	- 	38
Medical Device Regulation 	- 	85 	- 	85
COVID-19 Vaccine related costs 	165 	- 	- 	165
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,815 	2,197 	(7) 	8,005
% to Sales 	42.3% 	28.2% 	0.0% 	37.2%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	9,214 	3,080 	(7,275) 	5,019
% to Sales 	33.9% 	20.2% 	-17.2% 	11.8%
Intangible asset amortization expense 	1,487 	765 	- 	2,252
In-process research and development Impairments 	- 	49 	- 	49
Litigation Related 	(93) 	60 	7,070 	7,037
Loss/(gain) on securities 	76 	(5) 	- 	71
Restructuring related 	275 	- 	- 	275
Acquisition, integration and divestiture related 	- 	80 	- 	80
Medical Device Regulation 	- 	149 	- 	149
COVID-19 Vaccine related costs 	609 	- 	- 	609
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	11,568 	4,178 	(205) 	15,541
% to Sales 	42.6% 	27.4% 	-0.5% 	36.6%
Worldwide Total
Q2 2023 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q2 2023 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 15 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	3,873 	1,441 	(111) 	5,203
% to Sales 	30.1% 	20.7% 	-0.6% 	26.2%
Intangible asset amortization expense 	760 	254 	- 	1,014
In-process research and development Impairments 	610 	- 	- 	610
Loss/(gain) on securities 	394 	17 	- 	411
Restructuring related 	(14) 	72 	- 	58
Medical Device Regulation 	- 	60 	- 	60
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,623 	1,844 	(118) 	7,349
% to Sales 	43.7% 	26.5% 	-0.6% 	37.0%
Q1 2022 - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total

-- 16 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,365 	1,110 	(331) 	5,144
% to Sales 	32.8% 	16.1% 	-1.6% 	25.4%
Intangible asset amortization expense 	736 	259 	- 	995
Litigation Related 	21 	264 	100 	385
Loss/(gain) on securities 	102 	7 	- 	109
Restructuring related 	23 	80 	- 	103
Medical Device Regulation 	- 	70 	- 	70
COVID-19 Vaccine related costs 	276 	- 	- 	276
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,523 	1,790 	(231) 	7,082
% to Sales 	41.5% 	25.9% 	-1.1% 	35.0%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	8,238 	2,551 	(442) 	10,347
% to Sales 	31.5% 	18.4% 	-1.1% 	25.8%
Intangible asset amortization expense 	1,496 	513 	- 	2,009
In-process research and development Impairments 	610 	- 	- 	610
Litigation Related 	21 	264 	100 	385
Loss/(gain) on securities 	496 	24 	- 	520
Restructuring related 	9 	152 	- 	161
Medical Device Regulation 	- 	130 	- 	130
COVID-19 Vaccine related costs 	276 	- 	- 	276
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	11,146 	3,634 	(349) 	14,431
% to Sales 	42.6% 	26.2% 	-0.9% 	36.0%
Worldwide Total
Q2 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q2 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 17 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	4,186 	1,090 	(104) 	5,172
% to Sales 	31.7% 	16.1% 	-0.5% 	25.9%
Intangible asset amortization expense 	698 	260 	- 	958
Litigation Related 	7 	212 	- 	219
Loss/(gain) on securities 	177 	(13) 	- 	164
Restructuring related 	23 	69 	- 	92
Medical Device Regulation 	- 	78 	- 	78
COVID-19 Vaccine related costs 	377 	- 	- 	377
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	5,468 	1,696 	(104) 	7,060
% to Sales 	41.4% 	25.0% 	-0.5% 	35.3%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	12,424 	3,641 	(546) 	15,519
% to Sales 	31.5% 	17.6% 	-0.9% 	25.8%
Intangible asset amortization expense 	2,194 	773 	- 	2,967
In-process research and development Impairments 	610 	- 	- 	610
Litigation Related 	28 	476 	100 	604
Loss/(gain) on securities 	673 	11 	- 	684
Restructuring related 	32 	221 	- 	253
Medical Device Regulation 	- 	208 	- 	208
COVID-19 Vaccine related costs 	653 	- 	- 	653
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	16,614 	5,330 	(453) 	21,491
% to Sales 	42.2% 	25.8% 	-0.8% 	35.8%
Worldwide Total
Q3 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q3 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 18 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	3,223 	806 	(189) 	3,840
% to Sales 	24.5% 	11.9% 	-0.9% 	19.3%
Intangible asset amortization expense 	717 	260 	- 	977
In-process research and development Impairments 	173 	- 	- 	173
Litigation Related 	76 	136 	50 	262
Loss/(gain) on securities 	23 	(17) 	- 	6
Restructuring related 	31 	88 	- 	119
Acquisition, integration and divestiture related 	(104) 	300 	- 	196
Medical Device Regulation 	- 	88 	- 	88
COVID-19 Vaccine related costs 	821 	- 	- 	821
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	4,960 	1,661 	(139) 	6,482
% to Sales 	37.7% 	24.5% 	-0.7% 	32.5%
Pharmaceutical 	MedTech 	Unallocated
Reported Income Before Tax by Segment from Continuing Operations 	$ 	15,647 	4,447 	(735) 	19,359
% to Sales 	29.8% 	16.2% 	-0.9% 	24.2%
Intangible asset amortization expense 	2,911 	1,033 	- 	3,944
In-process research and development Impairments 	783 	- 	- 	783
Litigation Related 	104 	612 	150 	866
Loss/(gain) on securities 	696 	(6) 	- 	690
Restructuring related 	63 	309 	- 	372
Acquisition, integration and divestiture related 	(104) 	300 	- 	196
Medical Device Regulation 	- 	296 	- 	296
COVID-19 Vaccine related costs 	1,474 	- 	- 	1,474
Other 	- 	- 	(7) 	(7)
Adjusted Income Before Tax by Segment from Continuing Operations 	$ 	21,574 	6,991 	(592) 	27,973
% to Sales 	41.0% 	25.5% 	-0.7% 	35.0%
Worldwide Total
Q4 2022 QTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions
Worldwide Total
Q4 2022 YTD - Income Before Tax by Segment from Continuing Operations
Dollars in Millions

-- 19 of 21 --

Quarter to Date
First Quarter
April 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition,
integration and
divestiture related
Medical Device
Regulation
First Quarter
April 2, 2023
Non-GAAP
Cost of products sold 	6,687	$ 	(1,118) 	- 	(23) 	(206) 	5,340
Selling, marketing and admin expenses 	4,906 	(7) 	4,899
Research and development expense 	3,455 	(16) 	(34) 	(16) 	3,389
Other (Income) / Expense 	6,940 	(4) 	(6,900) 	- 	(26) 	(72) 	(222) 	(284)
In-process research and development Impairments 	49 	(49) 	-
Interest (Income) / Expense 	14 	14
Restructuring 	130 	(130) 	-
Provision for/(Benefit from) taxes on income 	(796) 	177 	1,622 	11 	32 	5 	16 	12 	105 	(11) 	23 	1,196
Net Earnings/(Loss) from Continuing Operations 	(491) 	945 	5,278 	38 	98 	37 	56 	52 	339 	11 	(23) 	6,340
Quarter to Date
Second Quarter
July 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation
Second Quarter
July 2, 2023
Non-GAAP
Cost of products sold 	6,462	$ 	(1,130) 	- 	(34) 	38 	- 	- 	5,336
Selling, marketing and admin expenses 	5,396 	(8) 	5,388
Research and development expense 	3,703 	- 	(44) 	(46) 	3,613
Other (Income) / Expense 	(384) 	- 	(137) 	- 	(38) 	1 	(156) 	- 	(714)
In-process research and development Impairments 	- 	- 	-
Interest (Income)/Expense 	(109) 	(109)
Restructuring 	145 	(145) 	-
Provision for taxes on income 	930 	177 	29 	- 	37 	12 	(1) 	15 	38 	17 	21 	1,275
Net Earnings from Continuing Operations 	5,376 	953 	108 	- 	108 	26 	- 	71 	126 	(17) 	(21) 	6,730
Year to Date
Six Months
July 2, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation
Six Months
July 2, 2023
Non-GAAP
Cost of products sold 	13,149	$ 	(2,248) 	- 	(57) 	(168) 	10,676
Selling, marketing and admin expenses 	10,302 	(15) 	10,287
Research and development expense 	7,158 	(16) 	(78) 	(62) 	7,002
Other (Income) / Expense 	6,556 	(4) 	(7,037) 	- 	(64) 	(71) 	(378) 	- 	(998)
In-process research and development Impairments 	49 	(49) 	- 	- 	-
Interest (Income)/Expense 	(95) 	(95)
Restructuring 	275 	(275) 	-
Provision for taxes on income 	134 	354 	1,651 	11 	69 	17 	15 	27 	143 	6 	44 	2,471
Net Earnings from Continuing Operations 	4,885 	1,898 	5,386 	38 	206 	63 	56 	123 	465 	(6) 	(44) 	13,070
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs

-- 20 of 21 --

Quarter to Date
First Quarter
April 3, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Acquisition,
integration and
divestiture related
Medical Device
Regulation 	Other
First Quarter
April 3, 2022
Non-GAAP
Cost of products sold 	6,018	$ 	(1,014) 	(14) 	(22) 	4,968
Selling, marketing and admin expenses 	4,812 	(6) 	4,806
Research and development expense 	3,355 	(32) 	3,323
Other (Income) / Expense 	(210) 	- 	- 	20 	- 	(411) 	- 	7 	(594)
In-process research and development Impairments 	610 	(610) 	-
Restructuring 	64 	(64) 	-
Provision for taxes on income 	632 	148 	(53) 	138 	8 	- 	96 	11 	- 	(96) 	79 	(2) 	961
Net Earnings from Continuing Operations 	4,571 	866 	53 	472 	50 	- 	315 	49 	- 	96 	(79) 	(5) 	6,388
Quarter to Date
Second Quarter
July 3, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Second Quarter
July 3, 2022
Non-GAAP
Cost of products sold 	6,322	$ 	(995) 	(14) 	(25) 	(194) 	- 	- 	- 	5,094
Selling, marketing and admin expenses 	5,120 	(6) 	5,114
Research and development expense 	3,585 	- 	(39) 	(110) 	3,436
Other (Income) / Expense 	(1) 	- 	(385) 	(18) 	- 	(109) 	28 	- 	- 	(485)
In-process research and development Impairments 	- 	- 	-
Restructuring 	71 	(71) 	-
Provision for taxes on income 	882 	148 	(29) 	- 	20 	- 	25 	13 	65 	(2) 	(78) 	- 	1,044
Net Earnings from Continuing Operations 	4,262 	847 	414 	- 	83 	- 	84 	57 	211 	2 	78 	- 	6,038
Quarter to Date
Third Quarter
Oct 2, 2022
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Third Quarter
Oct 2, 2022
Non-GAAP
Cost of products sold 	6,172	$ 	(958) 	(9) 	(29) 	(102) 	- 	- 	- 	5,074
Selling, marketing and admin expenses 	4,975 	(7) 	4,968
Research and development expense 	3,485 	- 	(42) 	(80) 	3,363
Other (Income) / Expense 	226 	- 	(219) 	(18) 	- 	(164) 	(195) 	- 	- 	(370)
In-process research and development Impairments 	- 	- 	-
Restructuring 	65 	(65) 	-
Provision for taxes on income 	862 	146 	(7) 	- 	19 	- 	43 	15 	96 	36 	(88) 	- 	1,122
Net Earnings from Continuing Operations 	4,310 	812 	226 	- 	73 	- 	121 	63 	281 	(36) 	88 	- 	5,938
Quarter to Date
Fourth Quarter
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Fourth Quarter
Jan 1, 2023
Non-GAAP
Cost of products sold 	6,084	$ 	(977) 	(25) 	(33) 	(160) 	- 	- 	- 	4,889
Selling, marketing and admin expenses 	5,339 	(9) 	- 	5,330
Research and development expense 	3,710 	- 	(46) 	(114) 	3,550
Other (Income) / Expense 	795 	- 	(262) 	(19) 	(196) 	(6) 	(547) 	- 	- 	(235)
In-process research and development Impairments 	173 	(173) 	-
Restructuring 	75 	(75) 	-
Provision for taxes on income 	613 	148 	(36) 	40 	19 	5 	2 	17 	199 	(4) 	47 	- 	1,050
Net Earnings from Continuing Operations 	3,227 	829 	298 	133 	100 	191 	4 	71 	622 	4 	(47) 	- 	5,432
Twelve Months
Jan 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Twelve Months
Jan 1, 2023
Non-GAAP
Cost of products sold 	24,596	$ 	(3,944) 	(62) 	(109) 	(456) 	20,025
Selling, marketing and admin expenses 	20,246 	(28) 	20,218
Research and development expense 	14,135 	- 	(159) 	(304) 	13,672
Other (Income) / Expense 	810 	- 	(866) 	(35) 	(196) 	(690) 	(714) 	- 	7 	(1,684)
In-process research and development Impairments 	783 	(783) 	- 	- 	-
Restructuring 	275 	(275) 	-
Provision for taxes on income 	2,989 	590 	(125) 	178 	66 	5 	166 	56 	360 	(66) 	(40) 	(2) 	4,177
Net Earnings from Continuing Operations 	16,370 	3,354 	991 	605 	306 	191 	524 	240 	1,114 	66 	40 	(5) 	23,796
Tax legislation and
other tax related
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Consumer Health
separation tax
related costs
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Year to Date
In-process
research and
development
Impairments
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Consumer Health
separation tax
related costs
Tax legislation and
other tax related

-- 21 of 21 --